Genoptix Inc. (Nasdaq: GXDX), a Carlsbad, Calif.-based provider of personalized medicine services for management of hematolymphatic disorders, has filed to sell 4.2 million shares in a secondary public offering. This would raise $128.1 million, based on yesterday's closing price of $30.5 per share.
Selling shareholders include original VC backers Enterprise Partners (1.27 million shares), Chicago Growth Partners, William Blair Capital Partners, Alliance Technology Ventures and Tullis-Dickerson. Each of those firms would still maintain a post-sale ownership position. www.genoptix.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.